Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions

Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical Schoo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singer MA, Cohen SR, Groth SL, Porbandarwalla S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/da4a9277206a42c9bea4f22a7cc3547e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da4a9277206a42c9bea4f22a7cc3547e
record_format	dspace
spelling	oai:doaj.org-article:da4a9277206a42c9bea4f22a7cc3547e2021-12-02T05:03:18ZComparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions1177-54671177-5483https://doaj.org/article/da4a9277206a42c9bea4f22a7cc3547e2013-07-01T00:00:00Zhttp://www.dovepress.com/comparing-bevacizumab-and-ranibizumab-for-initial-reduction-of-central-a13587https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical School, Minneapolis, Minnesota, USAPurpose: To examine short-term effects of ranibizumab versus bevacizumab on reduction of optical coherence tomography (OCT) central macular thickness (CMT) in patients with macular edema secondary to retinal vein occlusions (RVOs).Methods: This is a retrospective analysis in which patients with RVOs were injected with either bevacizumab or ranibizumab. At 2 weeks, all patients were injected with a dexamethasone intravitreal implant (Ozurdex®). CMT on OCT and best-corrected visual acuity were obtained at baseline, at 2 weeks (just prior to the dexamethasone intravitreal implant), and 6 weeks.Results: Sixty-four patients received injections (32 bevacizumab; 32 ranibizumab). At 2 weeks, bevacizumab group had a mean (±standard error of mean [SEM]) CMT reduction of 26.2% ± 3.4% versus 47% ± 3.5% reduction with ranibizumab (P < 0.0001). At 6 weeks, there was a 31.6% ± 3.2% CMT reduction with bevacizumab versus 52% ± 3.2% with ranibizumab (P < 0.0001). At 2 weeks, 15 (9%) of bevacizumab patients versus 25 (78.1%) ranibizumab patients achieved OCT CMT < 300 µm (P = 0.0192). At 6 weeks, 18 (56.3%) of bevacizumab compared to 30 (93.8%) of ranibizumab patients achieved CMT < 300 µm (P = 0.0010). Visual acuity was not significantly different at each time interval between the groups.Conclusion: Ranibizumab appears to have a greater effect in the short-term of decreasing macular edema on OCT when compared to bevacizumab in patients with RVOs.Keywords: anti-VEGF, central macular thickness, dexamethasone, intravitreal implant, macular edema, retinal vein occlusionSinger MACohen SRGroth SLPorbandarwalla SDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1377-1383 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Singer MA Cohen SR Groth SL Porbandarwalla S Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
description	Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical School, Minneapolis, Minnesota, USAPurpose: To examine short-term effects of ranibizumab versus bevacizumab on reduction of optical coherence tomography (OCT) central macular thickness (CMT) in patients with macular edema secondary to retinal vein occlusions (RVOs).Methods: This is a retrospective analysis in which patients with RVOs were injected with either bevacizumab or ranibizumab. At 2 weeks, all patients were injected with a dexamethasone intravitreal implant (Ozurdex®). CMT on OCT and best-corrected visual acuity were obtained at baseline, at 2 weeks (just prior to the dexamethasone intravitreal implant), and 6 weeks.Results: Sixty-four patients received injections (32 bevacizumab; 32 ranibizumab). At 2 weeks, bevacizumab group had a mean (±standard error of mean [SEM]) CMT reduction of 26.2% ± 3.4% versus 47% ± 3.5% reduction with ranibizumab (P < 0.0001). At 6 weeks, there was a 31.6% ± 3.2% CMT reduction with bevacizumab versus 52% ± 3.2% with ranibizumab (P < 0.0001). At 2 weeks, 15 (9%) of bevacizumab patients versus 25 (78.1%) ranibizumab patients achieved OCT CMT < 300 µm (P = 0.0192). At 6 weeks, 18 (56.3%) of bevacizumab compared to 30 (93.8%) of ranibizumab patients achieved CMT < 300 µm (P = 0.0010). Visual acuity was not significantly different at each time interval between the groups.Conclusion: Ranibizumab appears to have a greater effect in the short-term of decreasing macular edema on OCT when compared to bevacizumab in patients with RVOs.Keywords: anti-VEGF, central macular thickness, dexamethasone, intravitreal implant, macular edema, retinal vein occlusion
format	article
author	Singer MA Cohen SR Groth SL Porbandarwalla S
author_facet	Singer MA Cohen SR Groth SL Porbandarwalla S
author_sort	Singer MA
title	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
title_short	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
title_full	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
title_fullStr	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
title_full_unstemmed	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
title_sort	comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/da4a9277206a42c9bea4f22a7cc3547e
work_keys_str_mv	AT singerma comparingbevacizumabandranibizumabforinitialreductionofcentralmacularthicknessinpatientswithretinalveinocclusions AT cohensr comparingbevacizumabandranibizumabforinitialreductionofcentralmacularthicknessinpatientswithretinalveinocclusions AT grothsl comparingbevacizumabandranibizumabforinitialreductionofcentralmacularthicknessinpatientswithretinalveinocclusions AT porbandarwallas comparingbevacizumabandranibizumabforinitialreductionofcentralmacularthicknessinpatientswithretinalveinocclusions
_version_	1718400741383602176

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions

Ejemplares similares